NO-Donor Dihydroartemisinin Derivatives as Multitarget Agents for the Treatment of Cerebral Malaria.
暂无分享,去创建一个
J. Frangos | Elisabetta Marini | M. Bertinaria | R. Fruttero | A. Gasco | L. Carvalho | Y. C. Martins | Stefano Guglielmo | P. Orjuela-Sanchez | G. Zanini | A. Hofer
[1] J. Frangos,et al. Cerebral tissue oxygenation impairment during experimental cerebral malaria , 2013, Virulence.
[2] J. Frangos,et al. Transdermal Glyceryl Trinitrate as an Effective Adjunctive Treatment with Artemether for Late-Stage Experimental Cerebral Malaria , 2013, Antimicrobial Agents and Chemotherapy.
[3] J. Frangos,et al. Nitric Oxide Synthase Dysfunction Contributes to Impaired Cerebroarteriolar Reactivity in Experimental Cerebral Malaria , 2013, PLoS pathogens.
[4] X. Su,et al. Malaria biology and disease pathogenesis: insights for new treatments , 2013, Nature Medicine.
[5] J. Frangos,et al. A lactate dehydrogenase ELISA-based assay for the in vitro determination of Plasmodium berghei sensitivity to anti-malarial drugs , 2012, Malaria Journal.
[6] J. Frangos,et al. S-nitrosoglutathione Prevents Experimental Cerebral Malaria , 2012, Journal of Neuroimmune Pharmacology.
[7] J. Frangos,et al. Exogenous nitric oxide decreases brain vascular inflammation, leakage and venular resistance during Plasmodium berghei ANKA infection in mice , 2011, Journal of Neuroinflammation.
[8] John A. Frangos,et al. Nitric oxide protection against murine cerebral malaria is associated with improved cerebral microcirculatory physiology. , 2011, The Journal of infectious diseases.
[9] S. Parapini,et al. Amodiaquine analogues containing NO-donor substructures: synthesis and their preliminary evaluation as potential tools in the treatment of cerebral malaria. , 2011, European journal of medicinal chemistry.
[10] J. Frangos,et al. Artemether and Artesunate Show the Highest Efficacies in Rescuing Mice with Late-Stage Cerebral Malaria and Rapidly Decrease Leukocyte Accumulation in the Brain , 2011, Antimicrobial Agents and Chemotherapy.
[11] Kamolrat Silamut,et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial , 2010, The Lancet.
[12] R. Price,et al. Increased Asymmetric Dimethylarginine in Severe Falciparum Malaria: Association with Impaired Nitric Oxide Bioavailability and Fatal Outcome , 2010, PLoS pathogens.
[13] J. Frangos,et al. Immunopathology and Infectious Diseases Murine Cerebral Malaria Is Associated with a Vasospasm-Like Microcirculatory Dysfunction , and Survival upon Rescue Treatment Is Markedly Increased by Nimodipine , 2010 .
[14] C. Newton,et al. Diagnosis and management of the neurological complications of falciparum malaria , 2009, Nature Reviews Neurology.
[15] Y. Swica,et al. Proposal for the inclusion of misoprostol in the WHO model list of essential medicines , 2009 .
[16] R. Price,et al. Impaired nitric oxide bioavailability and l-arginine–reversible endothelial dysfunction in adults with falciparum malaria , 2007, The Journal of experimental medicine.
[17] J. Frangos,et al. Low nitric oxide bioavailability contributes to the genesis of experimental cerebral malaria , 2006, Nature Medicine.
[18] B. Neville,et al. Persistent neurocognitive impairments associated with severe falciparum malaria in Kenyan children , 2005, Journal of Neurology, Neurosurgery & Psychiatry.
[19] N. Anstey,et al. Low plasma arginine concentrations in children with cerebral malaria and decreased nitric oxide production , 2003, The Lancet.
[20] N. Anstey,et al. Nitric oxide in Tanzanian children with malaria: inverse relationship between malaria severity and nitric oxide production/nitric oxide synthase type 2 expression , 1996, The Journal of experimental medicine.
[21] P. Martorana,et al. Cardiovascular actions of the furoxan CAS 1609, a novel nitric oxide donor , 1995, British journal of pharmacology.